Tundra Space

Tundra Space

Clinical Research Directory

Browse clinical research sites, groups, and studies.

Back to Studies
ACTIVE NOT RECRUITING
NCT06774313
PHASE1

A Study to Assess the Adverse Events and How Subcutaneous (SC) Injections and Intravenous (IV) Infusions of ABBV-142 Move Through the Body of Healthy Adult Participants

Sponsor: AbbVie

View on ClinicalTrials.gov

Summary

This study is designed to assess the pharmacokinetic properties, safety, tolerability, and immunogenicity of ABBV-142 and determine whether predicted efficacious exposures can be safely achieved in humans.

Official title: A Phase 1a Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Immunogenicity of Single Ascending Doses of ABBV-142 in Healthy Adult Subjects and Single Doses of ABBV-142 in Healthy Adult Asian Subjects

Key Details

Gender

All

Age Range

18 Years - 55 Years

Study Type

INTERVENTIONAL

Enrollment

73

Start Date

2025-01-22

Completion Date

2026-04

Last Updated

2026-02-17

Healthy Volunteers

Yes

Interventions

DRUG

ABBV-142

Intravenous (IV) Infusion

DRUG

ABBV-142

Subcutaneous (SC) Injection

DRUG

Placebo

IV Infusion

DRUG

Placebo

SC Injection

Locations (1)

Acpru /Id# 271899

Grayslake, Illinois, United States